Norwegian medical-device developer Lifecare reported a narrower operating loss in the second quarter of 2026, alongside an extended cash runway through mid-2027, following strategic cost reductions and a NOK 25 million capital injection from warrant exercises.
The company posted an operating loss of NOK 10.6 million in Q2 2026, down from NOK 22 million in the same period of 2025 and NOK 31 million in Q1 2026. Net profit for the quarter reached NOK 4.5 million, driven by warrant revaluations and a NOK 2 million gain from the deconsolidation of its German unit. Revenue for the quarter totaled NOK 250,000, derived entirely from Norwegian government grants under the SkatteFUNN program.
Lifecare’s cash position increased to NOK 37 million at quarter-end, up from NOK 26 million at the start of the period, after raising NOK 25 million from warrant exercises in June. Management projected the current cash reserves would sustain operations through at least Q2 2027. Operating expenses declined by roughly NOK 14 million year-over-year, reflecting cost-cutting measures and a Q1 impairment adjustment.
The company is consolidating manufacturing operations in Bergen, Norway, following the wind-down of its German entity, which entered formal insolvency proceedings in late Q2 2026. Lifecare’s UK unit will focus on chemistry development as part of the restructuring. CEO Joacim highlighted progress in real-world evidence, including successful 6-month implant durations in three diabetic dogs, with one case—Truls—demonstrating continuous glucose data transmission to veterinarians.
Management reiterated its target of securing CE marking in 2027, though the CEO noted the timeline is becoming increasingly challenging. The company is proceeding directly to a pivotal CE study layout, bypassing a conceptual first-in-human study. Lifecare’s stock rose 6.15% in pre-market trading to $0.34, roughly 25.9% above its 52-week low of $0.27.
